Knock-Down of PRAME Increases Retinoic Acid Signaling and Cytotoxic Drug Sensitivity of Hodgkin Lymphoma Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Kewitz, Stefanie ^a   Staege, Martin S ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 26B1; CYTOTOXIC AGENT; ETOPOSIDE; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; RETINOIC ACID; ROSCOVITINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HODGKIN DISEASE; HUMANS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRETINOIN;

EID: 84873646293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055897     Document Type: Article

References (50)

1. Tzankov A, Dirnhofer S, (2006) Pathobiology of classical Hodgkin lymphoma. Pathobiology 73: 107-125.
2. Drexler HG, Minowada J, (2009) Hodgkin's disease derived cell lines: a review. Hum Cell 5: 42-53.
3. Sahin U, Neumann F, Tureci O, Schmits R, Perez F, et al. (2002) Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells. Blood 100: 4139-4145.
4. Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, et al. (2003) Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101: 1505-1512.
5. Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, et al. (2008) Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol 36: 886-896.
6. Körholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, et al. (2004) The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 216: 150-156.
7. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, et al. (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28: 3680-3686.
8. Lin HM, Teitell MA, (2005) Second malignancy after treatment of pediatric Hodgkin disease. J Ped Hematol Oncol 27: 28-36.
9. Ng AK, (2011) Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 154: 23-31.
10. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC, (2010) Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 28: 168-179.
11. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, et al. (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6: 199-208.
12. Yan M, Himoudi N, Basu BP, Wallace R, Poon E, et al. (2011) Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-aza-2′-deoxycytidine. Cancer Immunol Immunother 60: 1243-1255.
13. Epping MT, Bernards R, (2006) A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66: 10639-10642.
14. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
15. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B, (2002) Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133: 118-123.
16. Birtle Z, Goodstadt L, Ponting C, (2005) Duplication and positive selection among hominin-specific PRAME genes. BMC Genomics 6: 120.
17. Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, et al. (2010) Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 9: 226.
18. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, et al. (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122: 835-847.
19. Winkler C, Steingrube DS, Altermann W, Schlaf G, Max D, et al. (2012) Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses. Cancer Immunol Immunother 61: 1769-1779.
20. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, et al. (2011) High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 117: 3353-3362.
21. Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J, (1986) Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res 10: 487-500.
22. Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, et al. (1986) Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 68: 285-292.
23. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, et al. (1996) Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87: 3418-3428.
24. Schaadt M, Fonatsch C, Kirchner H, Diehl V, (1979) Establishment of a malignant, Epstein-Barr-virus (EBV)-negative cell-line from the pleura effusion of a patient with Hodgkin's disease. Blut 38: 185-190.
25. Diehl V, Kirchner HH, Burrichter H, Stein H, Fonatsch C, et al. (1982) Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 66: 615-632.
26. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, et al. (2004) DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Research 64: 8213-8221.
27. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, et al. (2007) Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res 31: 1521-1528.
28. Ocaya PA, Elmabsout AA, Olofsson PS, Törmä H, Gidlöf AC, et al. (2011) CYP26B1 plays a major role in the regulation of all-trans-retinoic acid metabolism and signaling in human aortic smooth muscle cells. J Vasc Res 48: 23-30.
29. Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP, (2007) Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46: 796-804.
30. Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, et al. (2010) Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 34: 1647-1655.
31. Ortmann CA, Eisele L, Nückel H, Klein-Hitpass L, Führer A, et al. (2008) Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 87: 809-818.
32. Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, et al. (2009) The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114: 3299-3308.
33. Kawano R, Karube K, Kikuchi M, Takeshita M, Tamura K, et al. (2009) Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma. J Clin Exp Hematop 49: 1-7.
34. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, et al. (2012) Gene expression profiling of microdissected Hodgkin Reed Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 120: 3530-3540.
35. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, et al. (2009) Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 119: 954-963.
36. Aebi S, Kroning R, Cenni B, Sharma A, Fink D, et al. (1997) All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res 3: 2033-2038.
37. Pettersson F, Colston KW, Dalgleish AG, (2001) Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 23: 273-279.
38. Grunt ThW, Dittrich E, Offterdinger M, Schneider SM, Dittrich Ch, et al. (1998) Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 78: 79-87.
39. Jozan S, Courtade M, Mathieu-Boué A, Lochon I, Bugat R, (1998) Cytotoxic effect of interferon-alpha2a in combination with all-trans retinoic acid or cisplatin in human ovarian carcinoma cell lines. Anticancer Drugs 9: 229-238.
40. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M, (2004) The tumor antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10: 4307-4313.
41. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, et al. (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114: 2945-2951.
42. Metkar SS, Manna PP, Anand M, Naresh KN, Advani SH, et al. (2001) CD40 Ligand-an anti-apoptotic molecule in Hodgkin's disease. Cancer Biother Radiopharm 16: 85-92.
43. Monge M, Colas E, Doll A, Gil-Moreno A, Castellvi J, et al. (2009) Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 30: 1288-1297.
44. Bradley EW, Ruan MM, Oursler MJ, (2008) Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway. J Biol Chem 283: 8055-8064.
45. De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, et al. (2011) BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 30: 223-233.
46. Affer M, Dao S, Liu C, Olshen AB, Mo Q, et al. (2001) Gene Expression differences between enriched normal and chronic myelogenous leukemia quiescent stem/progenitor cells and correlations with biological abnormalities. J Oncol 2011: 798592.
47. Foell JL, Max D, Giersberg C, Korholz D, Staege MS, (2008) Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine. Anticancer Res 28: 887-894.
48. Neumann I, Foell JL, Bremer M, Volkmer I, Korholz D, et al. (2010) Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate. Pediatr Blood Cancer 55: 464-470.
49. Kewitz S, Bernig T, Staege MS, (2012) Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells. Leuk Res 36: 773-778.
50. Kewitz S, Mueller J, Winkler C, Staege MS (2012) Retinoic acid signaling and immunotherapy of cancer. In: Cheng LH, Ito Y, editors. Retinoic acid: structure, metabolism and roles in disease. Hauppauge, Nova Science Publishers. 87-104.